FluoroPharma Medical, Inc. Restructures CardioPET License With Massachusetts General Hospital
September 27, 2018 at 09:00 am EDT
FluoroPharma Medical, Inc. announced that it has reached an agreement with The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to restructure its 2014 License Agreement for CardioPET. The restructuring reflects the current status of the molecule’s development, and enhanced collaboration opportunities between the Hospital and the Company. The terms of the amended license were not disclosed.